Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations  $\ \, \text{may continue.} \, \textit{See}$ Instruction 1(b).

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

## Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden 0.5 hours per response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Response															
1. Name and Address of Reporting Person *- THOMPSON STEPHEN B			2. Issuer Name and Ticker or Trading Symbol PLASMATECH BIOPHARMACEUTICALS INC [PTBI]						NC _	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner Officer (give title below) Other (specify below)						
(Last) (First) (Middle) PLASMATECH BIOPHARMACEUTICALS INC, 4848 LEMMON AVENUE, SUITE 517			3. Date of Earliest Transaction (Month/Day/Year) 05/11/2015								Vice F	resident Fina	ince			
(Street)			4	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line)  X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
DALLAS, TX 75219 (City) (State) (Zip)			(Zip)	Table I - Non-Derivative Securities Acqui						Acquire						
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Y			2A. Deemed Execution Date, if		3. T Cod (Ins	3. Transaction Code (Instr. 8)		4. Securities Acquir		aired 5. of (D) Ov	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)  Don		6. 7 Ownership o Form: E	Beneficial Ownership		
Common	stock		05/11/2015				ode A	75	,000 (2)	(D)	Price \$ 84 7.34	1,896			(Instr. 4)	
Reminder:	Report on a	separate line for eac	ch class of securities	beneficia	ally owne	d direc	Pe	ersons ontaine	who re	is forn	n are no	t required		nd unless t		1474 (9-02)
Reminder:	Report on a	separate line for eac	Table II - I	Derivativ	e Securi	ies Ac	Pe cc fo quired,	ersons ontaine orm dis	who reed in the plays a	is forn curre Benef	n are no ently val ficially O	ot required id OMB c		nd unless t		1474 (9-02)
1. Title of	2. Conversion	3. Transaction	Table II - I ( 3A. Deemed Execution Date, if	Derivativ (e.g., puts 4. Transact Code	re Securi s, calls, w tion of Deri ) Securi Acq (A) Disp (D)	ies Acarrant umber vative rities uired or osed o	Pecce fo quired, s, optio 6. Da Expir (Mon	ersons ontaine orm dis Dispos	who red in the plays a sed of, or vertible cisable a set	is form curre r Benef securi	n are no ently val ficially O	ot required lid OMB of Owned and of ing	8. Price of	nd unless t	of 10. Owners Form of Derivati Security Direct ( or Indire	11. Nature of Indire Beneficion Owners! (Instr. 4
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction	Table II - I ( 3A. Deemed Execution Date, if	Derivativ (e.g., puts 4. Transact Code	se Securi s, calls, w 5. N tion of Deri Secu Acq (A) Disp (D) (Insi	ies Ac arrant imber rities nired oor oosed o	Pecco fo fo for formal	Disposens, contained the Exercition D	who red in the plays a sed of, or vertible cisable a set	is form a curre r Benef securi	ficially Oties) 7. Title a Amount Underly Securities	ot required lid OMB of Owned and of ing	8. Price of Derivative Security (Instr. 5)	9. Number Derivative Securities Beneficially Owned Following Reported Transaction	of 10. Owners Form of Derivati Security Direct ( or Indirects)	11. Nature of Indire Beneficion Owners! (Instr. 4

### **Reporting Owners**

Donardin - Common Name / Addings	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
THOMPSON STEPHEN B PLASMATECH BIOPHARMACEUTICALS INC 4848 LEMMON AVENUE, SUITE 517 DALLAS, TX 75219			Vice President Finance		

### **Signatures**

/s/ Stephen B. Thompson	05/13/2015
**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 75,000 shares of restricted common stock will vest on 5/11/2016.
- (2) 100% accelerated vesting on change of control.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.	